- Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
- Immunovia announces updated financial calendar
- Immunovia Publishes Full Year Report for 2023
- Invitation to Immunovia's Q4 presentation
- Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs
More ▼
Key statistics
On Friday, Immunovia AB (publ) (IMMNOV:STO) closed at 1.75, 241.25% above the 52 week low of 0.514 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.82 |
---|---|
High | 1.83 |
Low | 1.70 |
Bid | -- |
Offer | -- |
Previous close | 1.79 |
Average volume | 2.39m |
---|---|
Shares outstanding | 45.29m |
Free float | 34.12m |
P/E (TTM) | -- |
Market cap | 80.97m SEK |
EPS (TTM) | -8.27 SEK |
Data delayed at least 15 minutes, as of Apr 19 2024 17:00 BST.
More ▼